Form 4: Adaptimmune Therapeutics Executive Granted Stock Options

John Lunger, Chief Patient Supply Officer of Adaptimmune Therapeutics PLC, was granted options to purchase ordinary shares in the company.

Summary

• On February 20, 2025, John Lunger, the Chief Patient Supply Officer of Adaptimmune Therapeutics PLC, was granted options to purchase ordinary shares of the company.
• He received options to purchase 1,612,032 ordinary shares with an exercise price of $0.1 per share, converted from GBP0.08.
• These options vest in installments, starting with 403,008 shares on February 20, 2026, and the remainder in monthly installments until February 20, 2029.
• Additionally, he received options to purchase 1,074,696 ordinary shares with an exercise price of $0.0013 per share, converted from GBP0.001.
• These options vest in annual installments of 268,674 shares starting February 20, 2026, and continuing until February 20, 2029, with expiration dates on March 15 of the following year.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. It's a routine event, but positive for aligning incentives.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Granting stock options is a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of the options are typical for executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the biotech industry, often used by companies like Amgen, Gilead, and Biogen.
• The vesting schedules, typically over 3-4 years, are designed to align executive incentives with long-term company performance, similar to practices observed at companies like Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders: Potential dilution of ownership if options are exercised.
• Employees: May view the option grant as a positive sign of company growth and stability.
• Executive: Incentivized to improve company performance to increase the value of the options.

Key Dates

Keywords

stock options, Adaptimmune Therapeutics, John Lunger, ordinary shares, executive compensation, Form 4